ABSTRACT
Wastewater-based epidemiology has emerged as a promising tool to monitor pathogens in a population, particularly when clinical diagnostic capacities become overwhelmed. During the ongoing COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), several jurisdictions have tracked viral concentrations in wastewater to inform public health authorities. While some studies have also sequenced SARS-CoV-2 genomes from wastewater, there have been relatively few direct comparisons between viral genetic diversity in wastewater and matched clinical samples from the same region and time period. Here we report sequencing and inference of SARS-CoV-2 mutations and variant lineages (including variants of concern) in 936 wastewater samples and thousands of matched clinical sequences collected between March 2020 and July 2021 in the cities of Montreal, Quebec City, and Laval, representing almost half the population of the Canadian province of Quebec. We benchmarked our sequencing and variant-calling methods on known viral genome sequences to establish thresholds for inferring variants in wastewater with confidence. We found that variant frequency estimates in wastewater and clinical samples are correlated over time in each city, with similar dates of first detection. Across all variant lineages, wastewater detection is more concordant with targeted outbreak sequencing than with semi-random clinical swab sampling. Most variants were first observed in clinical and outbreak data due to higher sequencing rate. However, wastewater sequencing is highly efficient, detecting more variants for a given sampling effort. This shows the potential for wastewater sequencing to provide useful public health data, especially at places or times when sufficient clinical sampling is infrequent or infeasible.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Canadian Institutes for Health Research (CIHR) operating grant to the Coronavirus Variants Rapid Response Network (CoVaRR-Net) to JR and BJS and the CFI project 'High throughput SARS-CoV-2 genome sequencing at the McGill Genome Center' to JR. DF was supported by the Fonds de Recherche du Quebec (FRQ) and a McGill MI4 Emergency COVID-19 Research Fund grant. SD was supported by FRQ and The Trottier and Molson Foundations. Data analyses were enabled by compute and storage resources provided by Compute Canada and Calcul Quebec.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This investigation was carried out in accordance with the legal mandate granted to public health authorities by the Public Health Act (LRQ, chapter S-2.2. Article 1; http://legisquebec.gouv.qc.ca/fr/ShowDoc/cs/S-2.2) as part of a public health intervention. All data was treated confidentially and analysed without nominal identification in accordance with the Policy on Information Protection and Security (PO-04-2014) of the National Public Health Institute of Quebec (INSPQ). The INSPQ therefore deemed this study exempt from ethical oversight according to provincial legislation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw wastewater sequencing data is available in the NCBI SRA database under BioProject ID PRJNA788395 (http://www.ncbi.nlm.nih.gov/bioproject/788395O). Viral genomes from clinical samples are available in GISAID under IDs listed in Tables S3 and S4. The SNV calling and post-variant-calling pipeline is available at: https://github.com/arnaud00013/Wastewater_surveillance_pipeline
